drugset
drugset / Trial / NCT05535920

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

NCT05535920 ↗

Phase 4 Completed 88 enrolled NephroNet, Inc. AstraZeneca · collab
RandomizedCrossoverOpen-labelPrevention

Summary

A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial

Timeline

Start
2022-04-14
Primary completion
2024-04-01
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Zirconium Cyclosilicate Other / unclassified 5 g Oral

Indications

No indication recorded.